A newly developed antibody-based treatment and protein-based vaccine reduced Alzheimer's symptoms in mouse models, researchers report.
Clinical trials for a preventative treatment for dementia was successful in mouse models. Researchers say human trials will begin in two years.
Researchers have engineered a vaccine using virus-like particles that target Tau tangles in mouse models of Alzheimer's disease. Following the administration of the vaccine, the mice developed antibodies that cleared tau proteins, with the response lasting for a month. The mice also showed improvements in memory based tests and had less brain shrinkage than their peers who did not receive the vaccine. This suggests the vaccine prevented apoptosis. Researchers hope to move the vaccine to human clinical trials in the future.
Researchers have successfully neutralized a genetic risk factor found in up to 80% of Alzheimer's patients. The ability to neutralize ApoE4 could help in the development of a vaccine, as well as other therapeutics, for late onset Alzheimer's.
A new DNA vaccine tested in mice significantly reduces tau and amyloid beta, two proteins implicated in Alzheimer's disease. The findings, researchers say, may pave the way for clinical trials in humans with the neurodegenerative disease.
Combining a tetanus vaccine with a virus particle may prove effective as a protection against Alzheimer's. The vaccine could also be used to treat allergies and psoriasis, researchers report.
Researchers are testing a new vaccine and oral medication that could delay or prevent Alzheimer's disease from developing in those with a genetic predisposition.
Researchers report a new DNA vaccine prompts an immune response to proteins associated with Alzheimer's disease.
Researchers have made a breakthrough discovery in the international quest to discover a new and potentially effective vaccine targeting the pathological proteins associated with Alzheimer’s disease.
